Clinical trials: IgA Nephropathy
Glomerulonephritis, IGA, Glomerulonephritis, Membranous
Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases
Morning urine samples of patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and minimal degenerative nephropathy confirmed by renal needle biopsy in our hospital from November 2020 to January…
- Conditions
- Glomerulonephritis, IGA, Glomerulonephritis, Membranous, Diabetic Nephropathies, Nephrosis, Lipoid
- Trial name
- NCT05797051
- Testing
- Microscopic hyperspectral imaging system
- Volunteers
- 80 people
- Sponsor
- Qianfoshan Hospital
IgA Nephropathy
Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy
The anti-hinge region antibodies would be a relevant biomarker of IgA nephropathy. Beyond a prognostic value (which could increase the risk of Renal Absolute), the longitudinal monitoring for these antibodies could be of…
- Trial name
- NIGA-RA (NCT02526966)
- Testing
- blood sample
- Where
- 15 sites in France
- Volunteers
- 68 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
IgA Nephropathy
Longterm Renal Oucomes of STOP-IgAN Trial Participants
IgA nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis in the Western world. Although most IgAN patients take a benign longterm course, about 20-30% progress to end-stage renal disease (ESRD) over 20…
- Trial name
- NCT03488368
- Testing
- observation
- Where
- Germany
- Volunteers
- 148 people
- Sponsor
- RWTH Aachen University
Primary Immunoglobulin a Nephropathy (IgAN)
Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in Chinese patients who have completed Nef-301 and continue to be treated with a stable dose of…
- Trial name
- NCT05534919
- Testing
- Nefecon
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Everest Medicines (Singapore) Pte. Ltd.
Immunoglobulin A Nephropathy, Healthy Subjects
Development of a Metabolic Assessment Tool for Chronic Kidney Disease
The purpose of this study is to examine the variation between individuals in blood lipid metabolites, and the changes in these metabolites in response to omega-3 fatty acids in patients with immunoglobulin A nephropathy (IgAN)…
- Trial name
- NCT01838239
- Testing
- Fish Oil
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Immunoglobulin A Nephropathy
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
To evaluate the long-term safety and tolerability of sibeprenlimab in subjects with IgAN
- Trial name
- NCT05248659
- Testing
- Sibeprenlimab 400 mg s.c. Q4weeks
- Where
- 158 sites in United States, Argentina and 29 more
- Volunteers
- 600 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
IgA Nephropathy (IgAN)
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
This study looks at how well and safely RG002C0106 works for patients with certain kidney disease: primary IgA nephropathy. It's a phase IIa trial done at several locations where both patients and doctors unknow what treatment is…
- Trial name
- NCT07305974
- Testing
- RG002C0106
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
Autosomal Dominant Polycystic Kidney Disease (ADPKD), Advanced-Chronic Kidney Disease (CKD)
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases
This is a prospective, clinical, multicentre study aimed to collect biological samples and study microbiota from subjects suffering from chronic kidney disease and from healthy volunteers.
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD), Advanced-Chronic Kidney Disease (CKD), Diabetic Kidney Disease (DKD), IgA Nephropathy (IgAN)
- Trial name
- BIOMIS-Nefro (NCT04689074)
- Testing
- Biological sample collection, Questionnaire, Medical examination
- Where
- 2 sites in Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Primary IgA Nephropathy
Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study
IgA nephropathy is the most common type of primary glomerulonephritis and might caused by deposition of immune complex containing IgA in mesangium and causing local immune activation.
- Trial name
- NCT02351752
- Testing
- Hydroxychloroquine Sulfate
- Where
- China
- Volunteers
- 20 people
- Sponsor
- LLiu
Systemic Lupus Erythematosus, Immunoglobulin A Nephropathy
The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy.
The study hypothesis: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of clinical manifestations. Its mechanisms are not well understood.
- Trial name
- NCT05132621
- Testing
- Smear
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Medical University of Warsaw
IgA Nephropathy
IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
The investigators are registering all biopsy-proven primary IgA nephropathy (IgAN) patients at recruited hospitals and developing a IgAN database in China.
- Trial name
- NCT03001947
- Testing
- No intervention
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Sun Yat-sen University
Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.
- Conditions
- Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, Membranous Nephropathy
- Trial name
- RENEW (NCT05162066)
- Testing
- BCX9930
- Where
- 11 sites in France, Italy and 2 more
- Volunteers
- 2 people
- Sponsor
- BioCryst Pharmaceuticals
Berger Disease, Bergers Disease
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to <18 years with primary immunoglobulin A nephropathy (IgAN).
- Conditions
- Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
- Trial name
- ADVANCE (NCT07498335)
- Testing
- Drug: Atrasentan
- Where
- 18 sites in United States, China and 5 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
IgAN, C3G
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
- Conditions
- IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)
- Trial name
- NCT06989359
- Testing
- ADX-038 Dose Level 2, ADX-038 Dose Level 1
- Where
- 38 sites in United States, Australia and 6 more
- Volunteers
- 45 people
- Sponsor
- ADARx Pharmaceuticals, Inc.
IgA Nephropathy
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy
IgA nephropathy (IgAN) is the most common type of glomerulonephritis worldwide. 15-40% of individuals diagnosed with IgAN, including children, will eventually progress to chronic renal insufficiency (CRI) and end stage renal…
- Trial name
- NCT00318474
- Testing
- Mycophenolate Mofetil (MMF), ACEi, FOS
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
IgA Nephropathy
Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
This study was about IgA nephropathy, a form of kidney disease characterized by the presence of blood and protein in the urine. This study was done to determine if the medication rituximab could reduce protein in the patient's…
- Trial name
- NCT00498368
- Testing
- Intravenous Rituximab, ACE/ARB, Omega-3 Fatty Acid Fish Oil Supplement
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Kidney Disease
Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN)
IgA nephropathy (IgA Nephropathy), or Berger's disease, is the most common form of primary glomerulonephritis. It is a major cause of end-stage renal failure, often leading to dialysis or kidney transplantation.
- Trial name
- Rep-IgAN (NCT07295808)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Limoges
Primary IgA Nephropathy
The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease
The objective of the study is to evaluate efficacy and safety of two different doses of NEFECON in the treatment of patients with primary IgA nephropathy (IgAN) at risk of developing end-stage renal disease, under rigorous blood…
- Trial name
- NEFIGAN (NCT01738035)
- Testing
- NEFECON
- Where
- 58 sites in Belgium, Czechia and 8 more
- Volunteers
- 150 people
- Sponsor
- Calliditas Therapeutics AB
Chronic Kidney Disease
Effect of Statins on IgG, IgA and IgM Level in Chronic Hemodialysis Patients
This is double blind randomized controlled trial on the statins effects on serum IgG, IgA and IgM level in chronic hemodialysis patients in Bandarabbas
- Trial name
- NCT01305317
- Testing
- Lipitor
- Where
- Iran
- Volunteers
- 74 people
- Sponsor
- Hormozgan University of Medical Sciences